Home/PRISM Biolabs/Dai Takehara

DT

Dai Takehara

President & CEO

Therapeutic Areas

PRISM Biolabs Pipeline

Drug	Indication	Phase
E7386	Oncology (undisclosed)	Phase 1
PRI-724	Undisclosed (β-catenin/CBP inhibitor)	Phase 1

Leadership Team at PRISM Biolabs

Hyi-Man Park, Ph.D.

Director, Research and Development Department

View full PRISM Biolabs profile